ReViVox
Development- Indications
- Botulinum toxin complications
Company intelligence / Profile preview
For DelNova Healthcare in India—fully integrated pharmaceutical/CDMO firm developing and manufacturing small molecule generics and complex formulations. No specific clinical trial results reported; operates commercially with a portfolio of generic products including bisacodyl tablets, famotidine tablets, melatonin oral solutions/tablets among others.[2][4]
For DelNova in the U.S.—developing ReViVox®, a rescue therapy targeting off-target muscle paralysis from botulinum toxin injections. Early-stage development with no published clinical results yet but addressing an unmet need where no approved therapies exist.[3]
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on DelNova Healthcare.